Antibiotics, such as Amoxicillin, are extremely effectual when used appropriately prior to surgical procedures. The expiration of the potent antimicrobial drug Moxatag, also known as Amoxicillin, on October 13, 2020, paves the way for additional development of this generic powerhouse. Study results recently released in Infection Control and Hospital Epidemiology reveal that timing is[…]
Amoxicillin Effective When Timed Optimally Before Surgery
Antibiotic, Drug Research & Development API, Patent Expiration 2020, TEVA API Tags: antibiotic Aug 18, 2014
Raloxifene Treatment for Breast Cancer and Liver Cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, OTC and Compounding Product, TEVA API Tags: breast cancer Mar 19, 2014
Positive Study Results As a common medication prescribed for post-menopausal women to treat and prevent osteoporosis, Raloxifene has now been recognized as a potential viable treatment for both breast and liver cancer. A recently released study, conducted at Oregon State University, demonstrated powerful data touting the use of Raloxifene to treat triple-negative breast cancer (TNBC)[…]
Desloratadine is Still Effectual and Tolerable for Allergy Sufferers
OTC and Compounding Product, TEVA API Tags: asthma Feb 07, 2014
Known as the brand name Clarinex, as well as Clarinex D 12 Hour, Desloratadine is a steadfast and tolerable treatment for allergies. Desloratadine offers anti-inflammatory benefits, as it is a selective H(1)-receptor antagonist. Known as a safe and effective antihistamine for both adults and children, it comes as no surprise that IMS Health released positive[…]
Shortage of Buprenorphine Affects Patients in Need of Pain Management and in Detoxification Programs
Analgesic, FDA Drug Shortage, OTC and Compounding Product, TEVA API Oct 17, 2013
The current shortage of the narcotic analgesic Buprenorphine CAS# 52485-79-7, also known as the brand name Buprenex, has created a significant concern. As an injectable medication administered to treat moderate to severe pain, Buprenorphine is not only used for pain management, it is also used to treat addiction to narcotic drugs through a rapid detoxification[…]
Drug Shortages Loom as Obamacare Commences
Drug Research & Development API, FDA Drug Shortage, LGM Pharma, OTC and Compounding Product, TEVA API Oct 15, 2013
Drug shortages continue to worry healthcare industry workers, especially with the launch of Obamacare on October 1, 2013. While notification has been prompt from the FDA as to which drugs are in danger of becoming in short supply, many medications which are already minimally available have not seen a respite. Falling Short The once planned[…]
FDA Gives New Indication for Paclitaxel
Chemotherapeutic / Anti-Neoplastic, New Indication Approval, OTC and Compounding Product, TEVA API Tags: Paclitaxel Sep 12, 2013
On September 6, 2013 the FDA approved a new indication for the formidable pancreatic cancer drug Paclitaxel. Known as the brand name Abraxane, which is marketed by Celgene, Paclitaxel is now officially indicated for the first-line treatment of patients with metastatic pancreatic cancer. Paclitaxel will be used in a combination treatment, alongside Gemcitabine, to treat[…]
Tadalafil Alongside Finasteride Once Daily Improved IPSS For Men
Blood Product, Cardiovascular Agent, OTC and Compounding Product, Patent Expiration 2017, TEVA API Tags: erectile dysfunction May 06, 2013
Tadalafil, also known as Cialis, is making headlines in pharmaceutical news. A study released on March 18, 2013 touted the use of tadalafil alongside finasteride for sizably improving scores for men on the International Prostate Symptom Score. Marketed by Eli Lilly, the patent for Cialis expires on November 21, 2017. The study, which was revealed[…]
Zmax is Azithromycin to the Max
Antibiotic, Bulk Active Ingredient, Patent Expiration 2017, TEVA API Tags: Pfizer Mar 04, 2013
The patent for the omnipotent Zmax is set to expire for Pfizer on May 30, 2017. This is extremely relevant for research and development as a generic formulation of this cogent drug, specifically azithromycin, can now be produced. Azithromycin is indicated for mild to moderate infections including acute bacterial sinusitis in adults due to haemophilus[…]
Will Once Weekly Fluoxetine Help Create New Brain Cells?
Antidepressant, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2017, TEVA API Tags: Antidepressantserotonin Jan 23, 2013
The expiration for the patent of the new formulation of Prozac, also known as the generic drug Fluoxetine Hydrochloride, is slated for November 1, 2017. As a common and effectual antidepressant, Fluoxetine HCl CAS# 56296-78-7, has proven to be a valuable treatment for patients in the United States and worldwide. In fact, antidepressant use in[…]
Acyclovir Successfully Halts the Spread of Herpes
Anti-Retroviral / Anti-HIV, Antiviral, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2017, TEVA API Jan 17, 2013
Acyclovir, known as the brand name Xerese, is an efficacious medication used to treat herpes labialis. Known commonly as cold sores or fever blisters, this form of the herpes virus is successfully treated with Acyclovir as a combination cream, alongside hydrocortisone. Marketed by Coria Laboratories, the patent for Xerese expires on January 24, 2017. The[…]
